<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198081</url>
  </required_header>
  <id_info>
    <org_study_id>0305-20</org_study_id>
    <nct_id>NCT00198081</nct_id>
  </id_info>
  <brief_title>Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)</brief_title>
  <official_title>A Phase II Trial of Celecoxib in Patients With IPMN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether the drug celecoxib has beneficial effects on
      people with pre-cancerous lesions of the pancreas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efforts at finding a successful chemotherapy for pancreatic cancer have been disappointing.
      Some patients are at increased risk of pancreatic cancer or may have pre-malignant pancreatic
      lesions which predispose them to later pancreatic cancer development. In these individuals,
      chemopreventative measures may block future development of pancreatic cancer. Human tissue
      studies, cell culture and animal models of pancreatic cancer strongly suggests that
      cyclooxygenase-2 (COX-2) may be a successful target for chemoprevention. COX-2 is
      overexpressed in human pancreatic cancers. Elevated COX-2 expression correlates with
      progression of premalignant precursors of pancreatic cancer in development models of hamster
      pancreatic cancer. Human tissue studies confirm increases in COX-2 expression with
      progression of premalignant precursors called intraductal papillary mucinous neoplasms
      (IPMNs) and pancreatic intraepithelial neoplasms (PanINs). Moreover, COX-2 inhibitors appear
      to have chemopreventative efficacy in the PC-1 homograft model of hamster pancreatic cancer.
      Demographic studies have suggested COX-2 inhibitors may confer protection from pancreatic
      cancer. We propose to conduct a pilot/phase II trial to determine the chemopreventative
      effects of the COX-2 inhibitor celecoxib in patients with premalignant pancreatic lesions.

      Patients registered to the study will take celecoxib twice daily for 6-8 weeks prior to
      surgery (if patient decides to have surgery for his/her condition). If subject is not a
      surgical candidate or puts off surgical treatment, subject will take celecoxib for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding and personnel to conduct study.
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months</measure>
    <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
    <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of PGE2 in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months</measure>
    <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
    <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of PGEM in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months</measure>
    <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
    <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months</measure>
    <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
    <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Changes in IPMN Progression.</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>Examine the short term effect of celecoxib on clinical progression of IPMN in the surgical arm; Examine the long term effect of celecoxib on clinical progression of IPMN in the medical arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreas Neoplasms</condition>
  <arm_group>
    <arm_group_label>Surgical Candidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COX-2 Inhibitor 6-8 weeks prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Candidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COX-2 Inhibitor 6-8 weeks prior to surgery</intervention_name>
    <description>400 mg BID 6-8 weeks prior to surgery</description>
    <arm_group_label>Surgical Candidate</arm_group_label>
    <other_name>Celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP</intervention_name>
    <description>400 mg BID for 6 months prior to follow-up EUS or ERCP</description>
    <arm_group_label>Medical Candidate</arm_group_label>
    <other_name>Celecoxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of IPMN

          -  ECOG Performance status of 0, 1, or 2

          -  Adequate liver function, bilirubin &lt; 1.5 times ULN, ALT or AST &lt; 2.5 times ULN

          -  Adequate renal function: creatinine &lt; 1.8

          -  Must be at least 18

        Exclusion Criteria:

          -  Use of COX-2 selective inhibitors within the last month

          -  More than occasional use of NSAIDS in last month (occasional use defined as up to
             twice weekly dosing)

          -  CA19-9 levels 1.5 times the ULN

          -  Active pancreatitis

          -  Taking sulphonylureas, fluconazole or lithium concomitantly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian M. Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>October 21, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>celecoxib for pancreas lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Surgical Candidate</title>
          <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
        </group>
        <group group_id="P2">
          <title>Medical Candidate</title>
          <description>COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP: 400 mg BID for 6 months prior to follow-up EUS or ERCP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">Eight (8) persons consented to participate but 3 withdrew prior to beginning protocol treatment.</participants>
                <participants group_id="P2" count="0">No enrollment on this arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0">No enrollment on this arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Surgical Candidate</title>
          <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Medical Candidate</title>
          <description>COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP: 400 mg BID for 6 months prior to follow-up EUS or ERCP</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IPMN type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Invasive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
        <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
        <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgical Candidate Baseline</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Surgery Candidate Surgery</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Surgical Candidate One Week</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O4">
            <title>Surgical Candidate 4 Weeks</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O5">
            <title>Surgical Candidate 6 Months</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of PGE2 in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
          <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
          <units>pg/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IPMN Adenoma-Part 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11800"/>
                    <measurement group_id="O2" value="13300"/>
                    <measurement group_id="O3" value="12100"/>
                    <measurement group_id="O4" value="19600"/>
                    <measurement group_id="O5" value="24000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN low-Part 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21000"/>
                    <measurement group_id="O2" value="13400"/>
                    <measurement group_id="O3" value="4700"/>
                    <measurement group_id="O4" value="36300"/>
                    <measurement group_id="O5" value="16000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN Invasive-Part 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="800"/>
                    <measurement group_id="O2" value="30000"/>
                    <measurement group_id="O3" value="15400"/>
                    <measurement group_id="O4" value="24800"/>
                    <measurement group_id="O5" value="3600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN NOS-Part 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10100"/>
                    <measurement group_id="O2" value="8700"/>
                    <measurement group_id="O3" value="9500"/>
                    <measurement group_id="O4" value="40300"/>
                    <measurement group_id="O5" value="7500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Changes in IPMN Progression.</title>
        <description>Examine the short term effect of celecoxib on clinical progression of IPMN in the surgical arm; Examine the long term effect of celecoxib on clinical progression of IPMN in the medical arm.</description>
        <time_frame>Baseline, 6 months, 1 year</time_frame>
        <population>Data never collected for surgical arm; medical arm of study never initiated.</population>
        <group_list>
          <group group_id="O1">
            <title>Surgical Candidate</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Medical Candidate</title>
            <description>COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP: 400 mg BID for 6 months prior to follow-up EUS or ERCP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Changes in IPMN Progression.</title>
          <description>Examine the short term effect of celecoxib on clinical progression of IPMN in the surgical arm; Examine the long term effect of celecoxib on clinical progression of IPMN in the medical arm.</description>
          <population>Data never collected for surgical arm; medical arm of study never initiated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of PGE2 in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
        <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
        <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgical Candidate Baseline</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Surgery Candidate Surgery</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Surgical Candidate One Week</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O4">
            <title>Surgical Candidate 4 Weeks</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O5">
            <title>Surgical Candidate 6 Months</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of PGE2 in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
          <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
          <units>pg/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IPMN Adenoma-Part 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="130"/>
                    <measurement group_id="O5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN low-Part 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN Invasive-Part 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN NOS-Part 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of PGEM in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
        <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
        <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgical Candidate Baseline</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Surgery Candidate Surgery</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Surgical Candidate One Week</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O4">
            <title>Surgical Candidate 4 Weeks</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O5">
            <title>Surgical Candidate 6 Months</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of PGEM in Urine at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
          <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
          <units>pg/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IPMN Adenoma-Part 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="354"/>
                    <measurement group_id="O4" value="431"/>
                    <measurement group_id="O5" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN low-Part 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="153"/>
                    <measurement group_id="O4" value="594"/>
                    <measurement group_id="O5" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN Invasive-Part 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="NA">Above the level of detection</measurement>
                    <measurement group_id="O3" value="850"/>
                    <measurement group_id="O4" value="453"/>
                    <measurement group_id="O5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN NOS-Part 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="184"/>
                    <measurement group_id="O4" value="417"/>
                    <measurement group_id="O5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
        <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
        <time_frame>Baseline, surgery, 1 wk, 4 wks, and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgical Candidate Baseline</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Surgery Candidate Surgery</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Surgical Candidate One Week</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O4">
            <title>Surgical Candidate 4 Weeks</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
          <group group_id="O5">
            <title>Surgical Candidate 6 Months</title>
            <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of PGEM in Serum at Baseline, Surgery, 1 wk, 4wks, and 6 Months</title>
          <description>Measured by Elisa at participant level - only participant level data available; not summarized across group</description>
          <units>pg/ml</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IPMN Adenoma-Part 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6.4"/>
                    <measurement group_id="O4" value="5.4"/>
                    <measurement group_id="O5" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN low-Part 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="5.9"/>
                    <measurement group_id="O5" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN Invasive-Part 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11.8"/>
                    <measurement group_id="O4" value="5.1"/>
                    <measurement group_id="O5" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPMN NOS-Part 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="7.2"/>
                    <measurement group_id="O4" value="4.3"/>
                    <measurement group_id="O5" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Surgical Candidate</title>
          <description>COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor 6-8 weeks prior to surgery: 400 mg BID 6-8 weeks prior to surgery</description>
        </group>
        <group group_id="E2">
          <title>Medical Candidate</title>
          <description>COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP: 400 mg BID for 6 months prior to follow-up EUS or ERCP</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC DISORDERS - OTHER, [CONGESTIVE HEART FAILURE]</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDERS - OTHER, [NEUROLEPTIC REACTION]</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>EKG CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>ARRTHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>PANCREATIC FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>EDEMA: LIMB SWELLING OF THE ARMS AND/OR LEGS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>FLU-TYPE SYMPTOMS (INCLUDING BODY ACHES, FEVER, CHILLS, TIREDNESS,LOSS OF APPETITE, COUGH)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - OTHER, [RUNNY NOSE]</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christian M. Schmidt, MD</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-8349</phone>
      <email>maxschmi@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

